Biliary Tract Neoplasms

Explore clinical trials studying Biliary Tract Neoplasms. Study availability and eligibility vary by location and protocol.

327 public trials 104 recruiting studies

Refine in advanced search Browse all conditions

Biliary Tract Neoplasms trial results

Active, Not Recruiting

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

NCT03478488

Conditions: Biliary Tract Diseases, Biliary Tract Neoplasms, Digestive System Diseases, +3 more
Locations: The Chinese people's liberation army (PLA) 81hospital Nanjing, Jiangsu, China

View Trial Details

Active, Not Recruiting

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

NCT03440450

Conditions: Advanced Solid Tumors, Biliary Tract Cancer, Biliary Tract Diseases, +5 more
Locations: Honor Health Research Institute Scottsdale, Arizona, United States

University of Arizona Cancer Center Tucson, Arizona, United States

Hoag Memorial Hospital Comprehensive Cancer Center Newport Beach, California, United States

Sarah Cannon Research Institute Denver, Colorado, United States

View Trial Details

Active, Not Recruiting

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)

NCT06975917

Conditions: Biliary Tract Cancer, Biliary Tract Cancers (BTC), Biliary Tract Diseases, +5 more
Locations: Ankara University Faculty of Medicine Department of Medical Oncology Ankara, Turkey (Türkiye)

View Trial Details

Active, Not Recruiting

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

NCT03695952

Conditions: Adenocarcinoma, Biliary Tract Cancer, Biliary Tract Diseases, +12 more
Locations: Changhoon Yoo Seoul, South Korea

View Trial Details

Active, Not Recruiting

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

NCT04308174

Conditions: Adenocarcinoma, Biliary Tract Diseases, Biliary Tract Neoplasms, +11 more
Locations: Asan Medical Center Seoul, South Korea

View Trial Details

Active, Not Recruiting

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics

NCT04584008

Conditions: Biliary Tract Diseases, Biliary Tract Neoplasms, Carcinoma, +42 more
Locations: Peking University Cancer Hospital Beijing, Beijing Municipality, China

View Trial Details

Active, Not Recruiting

Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC

NCT06490107

Conditions: Biliary Tract Cancer, Biliary Tract Diseases, Biliary Tract Neoplasms, +4 more
Locations: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, China

View Trial Details

Biliary Tract Neoplasms

Biliary Tract Neoplasms trial results

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics

Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC

Related conditions